Benign proliferative synovial lesion; localized or diffuse type. Common in knee (80%) and hip; presents with pain, swelling, recurrent effusion. MRI: low-signal intensity on T2 due to hemosiderin deposition. Treatment: synovectomy (arthroscopic/open); recurrence common in diffuse type. Targeted therapy: CSF1R inhibitors (pexidartinib) for unresectable cases.
What is the most common site affected by diffuse pigmented villonodular synovitis (PVNS)?
Which imaging modality is considered the investigation of choice for diagnosing pigmented villonodular synovitis (PVNS)?
What histological features are characteristic of pigmented villonodular synovitis (PVNS)?
Which of the following statements is true regarding the treatment of diffuse pigmented villonodular synovitis (PVNS)?
Which of the following is a common clinical feature of diffuse pigmented villonodular synovitis (PVNS)?
What is the typical duration before diagnosis for diffuse pigmented villonodular synovitis (PVNS)?
What is the main molecular basis for the development of pigmented villonodular synovitis (PVNS)?
Which of the following is a characteristic of localized tenosynovial giant cell tumor (TGCT)?
What is the role of CSF1R inhibitors in the management of pigmented villonodular synovitis (PVNS)?
What is the typical signal intensity of pigmented villonodular synovitis (PVNS) on T2-weighted MRI sequences?
